Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Inhibition of angiotensin II-induced contraction by losartan in human coronary arteries

Holmgren, Anton ; Pantev, Emil LU ; Erlinge, David LU orcid and Edvinsson, Lars LU (1998) In Journal of Cardiovascular Pharmacology 32(4). p.662-664
Abstract
The in vitro effects of angiotensin II (Ang II) in human vessels are not well studied. The development of specific Ang II-receptor antagonists has made it possible to delineate more carefully the receptor mechanisms involved. The objective of this study was twofold: to investigate the effect of Ang II on human coronary arteries and to study the effects of angiotensin II type 1 receptor blockade with losartan. The setting was contractile experiments with ring segments of coronary arteries. We observed that Ang II is a vasoconstrictor of human coronary arteries, with a pEC50 value of 9.26 +/- 0.22 and Emax of 68.7 +/- 9.61% of potassium-induced contraction. Losartan (10-100 nM) shifted the concentration-response curve of Ang II to the right,... (More)
The in vitro effects of angiotensin II (Ang II) in human vessels are not well studied. The development of specific Ang II-receptor antagonists has made it possible to delineate more carefully the receptor mechanisms involved. The objective of this study was twofold: to investigate the effect of Ang II on human coronary arteries and to study the effects of angiotensin II type 1 receptor blockade with losartan. The setting was contractile experiments with ring segments of coronary arteries. We observed that Ang II is a vasoconstrictor of human coronary arteries, with a pEC50 value of 9.26 +/- 0.22 and Emax of 68.7 +/- 9.61% of potassium-induced contraction. Losartan (10-100 nM) shifted the concentration-response curve of Ang II to the right, with pEC50 values of 7.64 +/- 0.10 and 7.00 +/- 0.15, respectively (p = 0.001), demonstrating the antagonistic properties of losartan. We also noted a decreased maximal response to Ang II after incubation of losartan, with Emax of 51.1 +/- 7.08% and 41.9 +/- 4.70% (p = 0.05), respectively. In conclusion, this is the first report describing the contractile effect of Ang II and the antagonizing effects of losartan in isolated human coronary arteries. (Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Cardiovascular Pharmacology
volume
32
issue
4
pages
662 - 664
publisher
Lippincott Williams & Wilkins
external identifiers
  • pmid:9781937
  • scopus:0031691836
ISSN
1533-4023
language
English
LU publication?
yes
id
8dba5fe5-f18d-4c8f-857b-145d7d297fbf (old id 1113109)
date added to LUP
2016-04-01 11:54:09
date last changed
2024-02-23 11:54:44
@article{8dba5fe5-f18d-4c8f-857b-145d7d297fbf,
  abstract     = {{The in vitro effects of angiotensin II (Ang II) in human vessels are not well studied. The development of specific Ang II-receptor antagonists has made it possible to delineate more carefully the receptor mechanisms involved. The objective of this study was twofold: to investigate the effect of Ang II on human coronary arteries and to study the effects of angiotensin II type 1 receptor blockade with losartan. The setting was contractile experiments with ring segments of coronary arteries. We observed that Ang II is a vasoconstrictor of human coronary arteries, with a pEC50 value of 9.26 +/- 0.22 and Emax of 68.7 +/- 9.61% of potassium-induced contraction. Losartan (10-100 nM) shifted the concentration-response curve of Ang II to the right, with pEC50 values of 7.64 +/- 0.10 and 7.00 +/- 0.15, respectively (p = 0.001), demonstrating the antagonistic properties of losartan. We also noted a decreased maximal response to Ang II after incubation of losartan, with Emax of 51.1 +/- 7.08% and 41.9 +/- 4.70% (p = 0.05), respectively. In conclusion, this is the first report describing the contractile effect of Ang II and the antagonizing effects of losartan in isolated human coronary arteries.}},
  author       = {{Holmgren, Anton and Pantev, Emil and Erlinge, David and Edvinsson, Lars}},
  issn         = {{1533-4023}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{662--664}},
  publisher    = {{Lippincott Williams & Wilkins}},
  series       = {{Journal of Cardiovascular Pharmacology}},
  title        = {{Inhibition of angiotensin II-induced contraction by losartan in human coronary arteries}},
  volume       = {{32}},
  year         = {{1998}},
}